Fluocortolone

Summary

Fluocortolone (CHEMBL251634) is an approved small molecule (ATC D07AC05); indicated across 1 condition including hemorrhoid.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC05 (+3 more)
• Indications: 1 condition
• Chemistry: 376.5 Da · C22H29FO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL251634
Name	Fluocortolone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9053
ATC	D07AC05, H02AB03, C05AA08, D07XC05
Molecular formula	C22H29FO4
Molecular weight	376.5
InChIKey	GAKMQHDJQHZUTJ-ULHLPKEOSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@H]1C(=O)CO)C)O)C)F

IUPAC name: (6S,8S,9S,10R,11S,13S,14S,16R,17S)-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one

Also known as: Fluocortolona, Fluocortolone, SH 742, SH-742, fluocortolone, FLUOCORTOLONE

Patent coverage: 3,901 distinct patent families (15,062 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemorrhoid	4	MONDO:0004872	EFO:0009552

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).